The round was led by 6 Dimensions Capital, the company formed earlier this year by the merger of WuXi Healthcare Ventures and Frontline BioVentures, along with Sijia Jianxin Fund.
November 7, 2017 -- AnchorDx of Guangzhou raised $28 million in a Series B round to develop precision oncology products using next-generation sequencing technology. The company’s major focus applies NGS to methylated circulating tumor DNA (ctDNA) to diagnose early stage cancer. The round was led by 6 Dimensions Capital, the company formed earlier this year by the merger of WuXi Healthcare Ventures and Frontline BioVentures, along with Sijia Jianxin Fund.
Anchor was established in 2015.
